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Abstract
Background—Individuals with monoclonal B-cell lymphocytosis (MBL) have been identified in
clinic outpatients, in unaffected relatives of patients with chronic lymphocytic leukemia (CLL),
and in general populations. MBL and its relationship with CLL have been actively investigated
over the last decade. This report systematically reviews the prevalence of MBL in the context of
the populations studied and the evolution of laboratory methods used to define MBL.
Methods—To identify published studies that have assessed the prevalence of MBL, we
systematically searched the MEDLINE® databases and consulted with members of the
International MBL Study Group. We reviewed the 10 articles that were identified by this process.
We abstracted information on study populations, laboratory tests, criteria for designating MBL,
and the reported frequencies.
Results—Three of the ten studies were published in 2009, three between 2007 and 2008, and
four between 2002 and 2004. Reported prevalences varied widely, ranging from 0.12 to 18.2%.
This variability was clearly associated with both the laboratory methods and the populations
studied. MBL was more common among older individuals and kindred of persons with CLL. The
most common MBL subtype was CLL-like MBL.
Conclusions—Large population-based studies of MBL that employ standardized laboratory
methods with a consensus case definition are needed to assess prevalence and establish risk
factors. These studies should include prospective follow-up of MBL cases to determine the
*Correspondence to: Youn K. Shim, Division of Health Studies, Agency for Toxic Substances and Disease Registry, Atlanta,
Georgia.yshim@cdc.gov.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of
the Agency for Toxic Substances and Disease Registry and Centers for Disease Control and Prevention.
NIH Public Access
Author Manuscript
Cytometry B Clin Cytom. Author manuscript; available in PMC 2010 October 25.
Published in final edited form as:
Cytometry B Clin Cytom. 2010 ; 78(Suppl 1): S10–S18. doi:10.1002/cyto.b.20538.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
relationship between MBL and CLL. Data from original studies should be reported in sufficient
detail to allow future synthesis of information from multiple studies, such as meta-analysis.
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epidemiology
INTRODUCTION
Monoclonal B-cell lymphocytosis (MBL) is an asymptomatic hematologic condition defined
by the presence of monoclonal B-lymphocytes detected in peripheral blood of persons who
do not have chronic lymphocytic leukemia (CLL), other B-lymphoproliferative disorders
(BLPD), or underlying conditions such as infectious and autoimmune diseases (1). MBL and
its relationship with CLL and other BLPD have been very active areas of investigation over
the last decade. Based on findings from a large population-based cancer screening study,
MBL appears to precede CLL by several years (2). Although the majority of individuals
with MBL do not develop CLL, some MBL cases are at excess risk of developing CLL
(3,4). In fact, the observation that MBL consistently precedes CLL (2) emphasizes the need
for future studies designed to delineate the early molecular events leading to CLL.
Ultimately, such studies may lead to the identification of novel therapeutic targets that can
be used to delay or prevent CLL progression.
CLL is the most common adult leukemia in North America and Europe; it is less frequent in
Asia and Africa (5). The reported age-adjusted incidence rate of CLL in the United States
between 1975 and 2006 was 4.43 per 100,000 persons (6). However, because of its long
asymptomatic period, the incidence of CLL is under-reported in cancer registries (7).
Despite this uncertainty, it is clear that the incidence of CLL rises dramatically with age and
that it is more common in men than women (7,8). As the proportion of older people has
increased with improved life expectancy in the Western world, the burden from CLL has
also increased. The American Cancer Society projected 15,490 new cases for 2009, a
substantial increase from the 11,168 new cases reported in 2005 (9). The disease burden is
also significant in the European Union, with an estimated 46,000 individuals in 2006 living
with CLL 5 years post-diagnosis (10).
Currently, detailed information on descriptive epidemiologic characteristics of MBL is not
available. The flow cytometry methods used to detect MBL vary from routine clinical
settings to detailed research studies. The reported prevalence of MBL also varies widely.
This report systematically reviews the reported prevalence of MBL in the context of the
populations studied and the evolution of laboratory methods used to define MBL.
METHODS
We searched Ovid MEDLINE® database from 1996 to July Week 4, 2009 and the Ovid
MEDLINE® In-Process & Other NonIndexed Citations database (dated August 3, 2009)
with the multifield search engine using truncation and wild cards. We selected nine articles
as outlined in Figure 1.
These articles were provided to participants in the International MBL Study Group (11),
who identified one additional article. The citations contained in this final set of 10 articles
were reviewed for any salient articles that had been missed; none were identified.
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The ten articles were reviewed and information on study population, laboratory tests, criteria
for designating MBL, and the frequency of MBL were abstracted. Where possible, we
recalculated prevalence rates for subgroups of MBL from the data reported in each study.
We did not calculate an aggregated prevalence estimate across all studies because the
laboratory methods utilized and the populations studied varied widely.
RESULTS
Characteristics of the Included Studies
Of the ten articles identified, nine were cross-sectional surveys (3,12–19) and one was a
longitudinal cohort study incorporating both baseline and follow-up data (20). All were
published between 2002 and 2009: three studies in 2009, three studies between 2007 and
2008, and four between 2002 and 2004.
Six studies originated from Europe (Italy n = 2; United Kingdom n = 3; Spain n = 1) and
four from North and South America (United States n = 3; Brazil n = 1). No studies from
other geographic regions met the inclusion criteria. The individuals studied came from
diverse settings. Three studies targeted general populations (12,13,20), one investigated a
blood donor population (14), three included outpatients in general clinics (3,15,16), and
three targeted clinically unaffected relatives of CLL patients (17–19). The number of
individuals included in these studies varied greatly, ranging from 33 in a study of CLL
kindred (18) to 5141 in a study of blood donors (14). Most studies targeted older adults, with
minimum age in the 40s. However, three studies included individuals less than 20-years-old
(12,14,17). Of the ten studies, only one study selected individuals based on the presence of
lymphocytosis (3).
Laboratory Methods and Criteria for MBL
Although all studies used multicolor flow cytometry to detect MBL, there were significant
differences in the methodologies employed. Some studies utilized two color or three color
antibody-fluorochrome combinations and analyzed relatively few cellular events. These
methods produced lower prevalence estimates (14,20).
Other recent studies made use of instrument and technical advances that allowed
multiplexed analysis with more antibody-fluorochrome combinations. These studies also
collected larger numbers of cells, which facilitated detection of very small populations of
MBL cells among normal lymphocytes. Four color to eight-color antibody-fluorochrome
combinations have been used to analyze as many as 5 × 105–5 × 106 total cellular events.
These protocols produced higher prevalence estimates (12,13).
Another common finding among most studies is the presence of three different types of
MBL cases, defined on the basis of CD19 positivity, CD5 presence or absence, and CD20
intensity. The most common type is CLL-like MBL. These MBL cells coexpress CD19 and
CD5 with dim expression of CD20, and are immunopheno-typically indistinguishable from
CLL cells. The second type is termed atypical CLL-like MBL, which differs from the
typical form in that CD20 expression is bright. The third type of MBL includes cases that do
not express CD5; these are classified as CD5− MBL or non-CLL-like MBL.
Although most studies attempted to detect immunoglobulin heavy-chain variable (IGHV)
gene rearrangement in MBL samples, negative results did not preclude MBL that had been
detected phenotypically. However, positive results did provide information on IGHV gene
family usage in MBL (12).
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Prevalence of MBL: General Populations and Blood Donors
Table 1 summarizes the prevalence estimates obtained from three studies that investigated
general populations and one study that investigated blood donors. The most recently
published studies included volunteers in geographically well-defined populations in Spain
(13) and Italy (12). The study in Spain examined 608 individuals who were over 40 years of
age; this study acquired the highest number of leukocyte events noted in this systematic
review (eight-color staining panel, acquisition of 5 × 106 events). The overall prevalence of
MBL in this Spanish study population was 14.3%. The study in Italy found an overall
prevalence of 7.4% among 1,725 individuals aged 18 years or older (five-color staining
panel, acquisition of 5 × 105 events). In contrast, a much lower prevalence of MBL was
reported from two studies that were conducted in the United States using less sensitive flow
cytometry methods. One was a blood donor study, which reported a prevalence of 0.12%
among 5,141 individuals 17 years or older (14). The other was an environmental health
study, which reported a prevalence of 0.6% among 1,926 individuals aged 40 years or older
(20).
Two of these four studies reported the MBL prevalence by subtype. The overall prevalence
of CLL-like MBL was 12.0% in the Spanish study and 5.2% in the Italian study. The overall
prevalence of non-CLL like subtype was 2.3% for both studies. Although the CLL-like
subtype represented the majority of the MBL cases detected in the two studies, the
proportion of CLL-like MBL among all MBL cases was somewhat higher in the Spanish
study (83.9%) than in the Italian study (69.5%). Both studies reported increasing prevalence
rates with increasing age. For overall MBL, the age-specific prevalences in the Spanish
study were 5.1% for the 40–49 years group and 5.3% for the 50–59 years group. The
prevalence sharply increased in the older age groups: 17.5% (60–69 years), 21.7% (70–79
years), 27.3% (80–89 years) and 75% (>89 years) (13). In the Italian study population, the
age-specific prevalences of CLL-like MBL were 0.8, 6.8, and 9.2% for participants aged
<50 years, 50–69 years, and >69 years, respectively. In contrast, the age-specific prevalence
of non-CLL like MBL did not rise until the >69 age group (12). Neither study provided the
breakdown of individuals by age group; therefore the stability of the age-specific estimates
could not be ascertained. Three studies reported male: female ratios, which ranged from 1.2
(20) to 1.8 (12).
Prevalence of MBL: Outpatient Populations
Three clinic-based studies (3,15,16) reported the prevalence of MBL among outpatients with
normal blood counts (Table 2). The flow cytometry methods used in these studies were
similar, except that the more recent study by Rawstron et al. (3) acquired 2.5 times more
events per sample. Of these three clinic-based studies, the two studies that included only
individuals in their 60s or older reported similar prevalence rates of overall MBL: 6.4 (15)
and 6.9% (3). The similarity in prevalence estimates is remarkable, considering that the two
studies are from two different countries. The other study, which included younger
outpatients, reported a lower prevalence (4.5%) (16).
One of these three studies also investigated CLL-like MBL among 2,228 outpatients aged
39–99 years who were referred for investigation of previous or current lymphocytosis (3).
The prevalence was 13.9%, which was much higher than that observed among outpatients
with normal blood counts using similar laboratory methods (3.5–5.1%) (3,16). Among all
MBL cases with normal blood counts, the proportion of CLL-like MBL ranged from 68.6
(15) to 78.0% (16). As in the population-based studies, the prevalence of CLL-like MBL
was higher in the older age group (16). Two studies reported a higher MBL prevalence
among men (male: female ratios of 1.3 and 2.1) (15,16).
Shim et al. Page 4
Cytometry B Clin Cytom. Author manuscript; available in PMC 2010 October 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Prevalence of MBL: Clinically Unaffected Relatives of CLL Patients
Table 3 summarizes MBL prevalence among clinically unaffected relatives of CLL patients.
In a study of clinically unaffected first-degree relatives of familial-CLL patients (18), the
overall prevalence of MBL was 18% (6/33). In another study of clinically unaffected first-
degree relatives of familial-CLL patients, the prevalence of CLL-like MBL was 13.5%
(8/59) (19).
With sporadic CLL, the prevalence of MBL was lower: 4.1% (3.6% for CLL-like and 0.6%
for atypical) among the 167 first-degree relatives of 42 families with only one CLL patient
per family (17). In this study, the prevalence was higher among men (male: female ratio of
3.2) and higher in the older age group (2.5% for the 40–60 years-old participants and 15.6%
for those older than 60 years).
DISCUSSION
As immunophenotyping by flow cytometry came into common use, it was evident that
monoclonal B-cells with the CLL-phenotype could be detected in the peripheral blood of
some individuals who did not have CLL or any other B-cell malignancy. A unified
nomenclature for this condition was lacking (21) until the term MBL was introduced in 2005
by the International Familial-CLL Consortium (1). The 10 articles included in this
systematic review collectively reveal several important considerations in assessing the
prevalence of MBL. Both the laboratory methods used and the populations studied have a
major impact on the reported prevalence rates. Although it is difficult to quantify their
respective contributions, some general tendencies are apparent.
Regarding laboratory methodology, the major factor that influences MBL detection is the
number of B-cells acquired for analysis (22). This impact is most clearly demonstrated by
Nieto et al. (13), who acquired 5 × 106 leukocytes and reported the highest prevalence of
MBL among all general population studies. Their reported prevalence approached that in
familial-CLL kindreds reported by Marti et al. (18). In the Nieto study, 50 monoclonal B-
cell events were required to define MBL, and the clonal B-cells in many of the MBL cases
represented a very low proportion (median: 0.38%, interquartile range: 0.14–4.2%) of the
total B-cell population (13). It is not clear whether the study of familial-CLL kindreds was
also capable of detecting such low levels of monoclonal B-cells. It would be interesting to
know what the MBL prevalence would have been in the kindred study if the laboratory
methods employed by Nieto et al. had been used. In any case, the most clinically relevant
issue is the likelihood that MBL progresses to CLL or some other significant endpoint. The
size of the clone in absolute and relative terms, as well as the total B-cell count and the total
lymphocyte count, should be explored to identify the most predictive combination of
prognostic factors.
Another laboratory source of variability that could influence MBL prevalence estimates is
the ability to identify unique clonotypes by combinatorial patterns of staining. The studies
that employed two different fluorescent labels could identify only four phenotype
combinations. Five-color methods can distinguish 32 combinations, and eight-color methods
can distinguish 256. Although it is not possible to visualize so many combinations at once,
distinct populations can be identified by sequential gating or graphical representation of
multivariate analysis (e.g. principal component analysis of flow cytometry data) (23). In
addition, the intensity of staining for each receptor reflects differential expression, providing
further capability to identify unique clonotypes (24).
Despite the variability in prevalence estimates resulting from the differences in laboratory
methodologies, it is clear from this systematic review that MBL is more common among
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older adults and is most common among first-degree relatives of familial-CLL patients. The
age-related trend was consistent across the studies regardless of the sources of the study
population. These features parallel those of CLL, which is one of the most age-related of all
malignancies and has a strong familial risk.
Other demographic risk factors are less certain or remain unexplored. Although male excess
has been well documented in CLL, our systematic review shows that the gender difference
appears to be less pronounced in MBL. This difference may be real or may be an artifact.
The male: female ratio ranged from 1.2–1.8 in general population-based studies and from
1.3–2.1 in outpatient-based studies. However, none of the studies reported the age-sex
specific prevalence, and it is possible that women included in the studies were older than
men. In fact, we speculate that future refinements in defining subtypes of MBL may
delineate a condition with a higher probability of progression, and in this group the male:
female ratio may coincide with that of CLL more closely.
No prevalence study of MBL from Asia or Africa was available for the review, and the
studies included in this review did not report MBL prevalence by ethnic group. Given the
fact that CLL is reportedly less common among Asians (5), one might speculate that this
could be due to a lower prevalence of MBL, or a lower risk of progression from MBL to
CLL, or a combination. To our knowledge, at this time, no study has been conducted to
address these questions.
The reported subgroupings of MBL contain intriguing but inconsistent characterizations that
do not allow a formal classification scheme. This inconsistency is due partly to differences
in laboratory immunophenotyping methods and partly to a lack of consensus case definitions
for MBL subgroups. Of particular importance is the distinction between “low-count” and
“high-count” MBL. The total lymphocyte count, total B-cell count, and the proportion of
monoclonal B-cells are all important parameters to explore in optimizing the definition of
low-count and high-count subtypes. An optimized classification system is essential in
assessing etiology, pathogenesis, and the likelihood of progression (25).
Studies of MBL will provide a greater understanding of the interaction between genetic and
environmental factors in the natural history of CLL and other BLPD. Although CLL has
strong familial associations, the overall genetic basis for the disease remains unclear (26).
Both biological agents (27) and chemical exposures have been linked to CLL (28), including
the herbicide Agent Orange (29). However, studies to date have not been able to establish a
statistically significant association between any environmental agent and CLL, and an
extrinsic environmental cause for CLL remains elusive. As MBL occurs earlier and has a
much higher prevalence than CLL, it provides a more sensitive marker of biological effect
for epidemiologic studies (30).
In summary, large population-based studies of MBL that employ standardized laboratory
methods with consensus case definition are needed to assess prevalence and establish risk
factors. These studies should include follow-up of MBL cases to determine the relationship
between MBL and B-cell malignancies (particularly CLL), including risk factors associated
with progression. They also should explore correlations with molecular markers and
potential gene-environment interactions. Finally, our review underscores the importance of
reporting data from original studies in sufficient detail to allow future synthesis of
information from multiple studies, including meta-analysis.
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Fig. 1.
Flow diagram of article identification to be included in this systematic review.
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